NCT00436293已完成2 期
A Randomized Phase II Study of Concurrent Cisplatin-radiotherapy With or Without Neoadjuvant Chemotherapy Using Taxotere and Cisplatin in Advanced Nasopharyngeal Carcinoma (NPC)
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- Sanofi
- 入组人数
- 61
- 试验地点
- 1
- 主要终点
- Treatment response is evaluated by correlating findings on clinical examination, endoscopy, biopsy, Computed tomography or Magnetic resonance imaging as appropriate.
研究概览
简要总结
Primary objective:
To assess and compare the toxicities of patients with advanced NPC treated with concurrent cisplatin-radiotherapy with or without neoadjuvant Taxotere (docetaxel) and cisplatin.
Secondary objective:
To assess tumor control and survival
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •International Union against Cancer stages III and IV newly diagnosed NPC
排除标准
- •Inadequate bone marrow reserve
- •Inadequate renal function
- •Other primary malignancy
- •Evidence of distant metastases
- •The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
研究组 & 干预措施
2
Active Comparator
Cisplatin and radiotherapy alone without neo-adjuvant chemotherapy
干预措施: Cisplatin (Drug)
1
Experimental
Neo-adjuvant Taxotere followed by cisplatin and radiotherapy
干预措施: Docetaxel (Drug)
结局指标
主要结局
Treatment response is evaluated by correlating findings on clinical examination, endoscopy, biopsy, Computed tomography or Magnetic resonance imaging as appropriate.
时间窗: From administration of drug to end of study
次要结局
- Adverse Events(From administration of drug to end of study)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
2 期
A phase II study of Conbination therapy of Cisplatin/Pemetrexed/Bavacizumab in previously untreated patients with StageIIIB/IV or recurrent disease nonsquamous non-small cell lung cancernon-small cell lung cancerJPRN-UMIN000006874Fukushima medical University37
终止
2 期
Cisplatin and Nab-paclitaxel for (N2) Defined NSCLCStage IIIA Non-Small Cell Lung CancerNCT02276560UNC Lineberger Comprehensive Cancer Center1
招募中
2 期
Efficacy and safety of the combination of Cisplatin plus Nab-paclitaxel and Nivolumab with radiotherapy after maximal tumor resection in non-metastatic muscle
invasive Bladder Cancer. (CA209-6E8, CNN-BC trial)2024-518937-26-00Fondazione Policlinico Universitario Agostino Gemelli IRCCS24
已完成
3 期
Randomized, comparative clinical study of cisplatin and docetaxel combination chemotherapy and mitomycin, vindesine and cisplatin (MVP) combination chemotherapy with concurrent thoracic radiation therapy for locally advanced unresectable non-small-cell lung cancer (OLCSG0007)inoperable locally advanced non-small-cell lung cancerJPRN-C000000085Okayama Lung Cancer Study Group (OLCSG)200
已完成
2 期
A Study of Induction and Maintenance Treatment of Advanced or Metastatic Non Squamous Non-Small Cell Lung CancerNon-Small-Cell Lung CancerNCT00867009Eli Lilly and Company113